These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27141979)

  • 1. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis.
    Bohn B; Schöfl C; Zimmer V; Hummel M; Heise N; Siegel E; Karges W; Riedl M; Holl RW;
    Cardiovasc Diabetol; 2016 May; 15():72. PubMed ID: 27141979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat prescriptions of guideline-based secondary prevention medication in patients with type 2 diabetes and previous myocardial infarction in Dutch primary care.
    Kasteleyn MJ; Wezendonk A; Vos RC; Numans ME; Jansen H; Rutten GE
    Fam Pract; 2014 Dec; 31(6):688-93. PubMed ID: 25106412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction.
    Shen L; Shah BR; Nam A; Holmes D; Alexander KP; Bhatt DL; Ho PM; Peterson ED; He B; Roe MT
    Am Heart J; 2014 Jun; 167(6):840-5. PubMed ID: 24890533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the Tromsø Study 2015-16.
    Hopstock LA; Morseth B; Cook S; Eggen AE; Grimsgaard S; Lundblad MW; Løchen ML; Mathiesen E; Nilsen A; Njølstad I
    Eur J Prev Cardiol; 2022 Mar; 29(2):362-370. PubMed ID: 33778888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction.
    Di Martino M; Kirchmayer U; Agabiti N; Bauleo L; Fusco D; Perucci CA; Davoli M
    BMJ Open; 2015 Jun; 5(6):e007866. PubMed ID: 26063569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI.
    Droz-Perroteau C; Blin P; Dureau-Pournin C; Thomas D; Danchin N; Tricoire J; Paillard F; Hercberg S; Guize L; Guiard E; Maïzi H; Bernard MA; Bénichou J; Moore N
    Therapie; 2019 Sep; 74(4):459-468. PubMed ID: 30878144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Faggiano P; Fattirolli F; Frisinghelli A; Piccioli L; Dasseni N; Silverii MV; Albricci L; D'Ambrosio G; Garrì R; Esposito L; Giallauria F
    Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31107039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of secondary prevention medication after myocardial infarction - the role of general practitioners and patients.
    Bally K; Buechel RR; Buser P; Tschudia P; Martinaa B; Zeller A
    Swiss Med Wkly; 2013; 143():w13896. PubMed ID: 24193548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts.
    Rivier CA; Acosta JN; Leasure AC; Forman R; Sharma R; de Havenon A; Spatz ES; Inzucchi SE; Kernan WN; Falcone GJ; Sheth KN
    J Am Heart Assoc; 2024 May; 13(9):e033322. PubMed ID: 38639369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
    BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index in early and middle adult life: prospective associations with myocardial infarction, stroke and diabetes over a 30-year period: the British Regional Heart Study.
    Owen CG; Kapetanakis VV; Rudnicka AR; Wathern AK; Lennon L; Papacosta O; Cook DG; Wannamethee SG; Whincup PH
    BMJ Open; 2015 Sep; 5(9):e008105. PubMed ID: 26373398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
    Chowdhury TA; Lasker SS; Dyer PH
    J Intern Med; 1999 Jun; 245(6):565-70. PubMed ID: 10395185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of suboptimal long-term secondary prevention of acute myocardial infarction: the structural interview method and physical examinations.
    Sakalaki M; Barywani S; Rosengren A; Björck L; Fu M
    BMC Cardiovasc Disord; 2019 Nov; 19(1):243. PubMed ID: 31694556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.